研究单位：[1]Merck Sharp & Dohme LLC[2]Beijing Cancer hospital-Digestive Oncology ( Site 0001),Beijing,Beijing,China,100142[3]Beijing Peking Union Medical College Hospital-Medical Oncology ( Site 0011),Beijing,Beijing,China,100730[4]Chongqing University Cancer Hospital-Medical Oncology ( Site 0012),Chongqing,Chongqing,China,400030[5]Fujian Provincial Cancer Hospital-oncology department ( Site 0009),Fuzhou,Fujian,China,350014[6]The First Affiliated Hospital, Sun Yat-sen University ( Site 0014),Guangzhou,Guangdong,China,510000[7]Guangdong Provincial People's Hospital ( Site 0035),Guangzhou,Guangdong,China,510080[8]The Sixth Affiliated Hospital of Sun Yat-sen University-Oncology ( Site 0048),Guangzhou,Guangdong,China,510655[9]Cancer Hospital of Shantou University Medical College ( Site 0036),Shantou,Guangdong,China,515041[10]Guangxi Medical University Affiliated Tumor Hospital ( Site 0039),Nanning,Guangxi,China,530201[11]Harbin Medical University Cancer Hospital-Harbin Medical University Cancer Hospital ( Site 0007),Harbin,Heilongjiang,China,150081[12]Henan Cancer Hospital-henan cancer hospital ( Site 0015),Zhengzhou,Henan,China,450000[13]Tongji Hospital Tongji Medical,Science & Technology-oncology ( Site 0018),Wuhan,Hubei,China,430000[14]Wuhan Union Hospital Cancer Center-Cancer Center ( Site 0008),Wuhan,Hubei,China,430022[15]The Third Xiangya Hospital of Central South University ( Site 0031),Changsha,Hunan,China,410013[16]The Affiliated Jiangyin Hospital of Southeast University Medical College ( Site 0037),Jiangyin,Jiangsu,China,214400[17]Nanjing Drum Tower Hospital The Affiliated Hospital of Nanjing University Medical School-Oncology (,NanJing,Jiangsu,China,210008[18]The first affiliated hospital of China medical university ( Site 0043),Shenyang,Liaoning,China,110001[19]Tangdu Hospital of Fourth Military Medical University of Chi-General Surgery ( Site 0045),Xi'an,Shaanxi,China,710038[20]Jinan Central Hospital-oncology department ( Site 0021),Jinan,Shandong,China,250013[21]Shandong Cancer Hospital ( Site 0041),Jinan,Shandong,China,250117[22]Fudan University Shanghai Cancer Center-Oncology ( Site 0046),Shanghai,Shanghai,China,200032[23]Shanghai East Hospital ( Site 0022),Shanghai,Shanghai,China,200120[24]Shanghai Changhai Hospital ( Site 0024),Shanghai,Shanghai,China,200433[25]Shanxi Cancer Hospital ( Site 0032),Taiyuan,Shanxi,China,030000[26]West China Hospital of Sichuan University ( Site 0044),Cheng Du,Sichuan,China,610041[27]Sichuan Cancer Hospital ( Site 0050),Chengdu,Sichuan,China,610042[28]Tianjin Medical University Cancer Institute and Hospital-Gastric oncology ( Site 0019),Tianjin,Tianjin,China,300060[29]Xinjiang Medical University Cancer Hospital - Urumchi ( Site 0049),Urumchi,Xinjiang,China,830011[30]Yunnan Province Cancer Hospital-Colorectal surgery ( Site 0006),Kunming,Yunnan,China,650106[31]Zhejiang Cancer Hospital-oncology-abdominal neoplasms ( Site 0028),Hangzhou,Zhejiang,China,310022
In this study, Chinese participants with MSI-H or dMMR advanced colorectal cancer will be assigned to receive either pembrolizumab or the Investigator's choice of 1 of 6 standard of care (SOC) chemotherapy regimens for treatment. There is no hypothesis testing for this study.
